(NASDAQ: BIIB) Biogen's forecast annual revenue growth rate of -2.41% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 7.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Biogen's revenue in 2025 is $9,816,400,000.On average, 25 Wall Street analysts forecast BIIB's revenue for 2025 to be $1,356,979,599,369, with the lowest BIIB revenue forecast at $1,319,336,599,328, and the highest BIIB revenue forecast at $1,389,202,534,904. On average, 25 Wall Street analysts forecast BIIB's revenue for 2026 to be $1,328,804,202,137, with the lowest BIIB revenue forecast at $1,226,731,009,504, and the highest BIIB revenue forecast at $1,391,434,153,785.
In 2027, BIIB is forecast to generate $1,344,498,651,695 in revenue, with the lowest revenue forecast at $1,229,091,572,878 and the highest revenue forecast at $1,448,191,709,510.